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Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as an early marker protein
for kidney dysfunction in various clinical settings. In this prospective study we evaluated
serial changes of serum and urinary NGAL within the first 7 days after kidney transplanta-
tion in 170 consecutive recipients. The main focus of this study was to assess the perfor-
mance of serum and urinary NGAL in the prediction of delayed graft function (DGF) and
two-year graft and patient survival. Serum and urine samples of 170 patients undergoing
primary kidney transplantation from October 2010 to December 2012 were prospectively
collected from day 0 to 7. NGAL was analyzed by ELISA. Multivariate regression models,
receiver-operating characteristics (ROC), and areas under ROC curves (AUC) were used
to identify predictors of DGF. DGF occurred in 52 patients (30.6%). Serum (AUC = 0.869)
and urinary NGAL (AUC = 0.872) on postoperative day (POD) 2 could accurately predict
DGF compared to serum creatinine (AUC = 0.619). Multivariate analyses revealed donor
age, serum and urinary NGAL significantly associated with DGF (p<0.001). Recipient age
was the only significant factor in a cox regression model influencing two-year graft and
patient survival. In conclusion, serum and urinary NGAL are early predictors of DGF after
kidney transplantation.
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Introduction
Early allograft dysfunction as well as long-term graft loss still represent major obstacles to
successful organ transplantation. Besides immunological reactions due to donor and recipi-
ent incompatibility, ischemia-reperfusion injury (IRI) of the transplanted organ is the major
process negatively affecting allograft function early after transplantation and long-term graft
survival. Thus it is important to find new biomarkers that will rapidly and reliably detect
acute and chronic allograft rejection as well as delayed graft function (DGF) [1]. Among a
series of novel markers identified by high-throughput expression analyses was NGAL, a small
member of the lipocalin family of lipophilic substrate binding proteins, that was found to be
dramatically up-regulated in transplanted hearts immediately after transplantation [2].
NGAL was first described by Kjeldsen and Cowland as a protein associated with human neu-
trophil gelatinase [3]. Later, NGAL was also found to be synthesized in large amounts in the
course of kidney injury where it was explored as a marker for compromised organ function
[4,5].
DGF is a common complication after kidney transplantation, especially with increasing
numbers of suboptimal donors, such as expanded criteria donors. It is associated with
decreased short- and long-term graft survival rates [6].
DGF is usually diagnosed by need for dialysis, diuresis and plasma creatinine. However,
plasma creatinine is affected by other factors such as body weight, age, sex and muscle metabo-
lism [7].
Moreover, the detectable rise in serum creatinine occurs at a stage where a significant dam-
age has already happened to the graft as late indicator of injury and rejection and recovery
becomes challenging [8]. This signifies the need of an accurate and early biomarker of graft
injury and rejection.
NGAL was shown to be an accurate biomarker of kidney injury in various experimental
and clinical settings [9]. Hall et al [10] could demonstrate that NGAL, measured on the
first postoperative day, could predict the need for dialysis in the first week after transplanta-
tion whereas serum creatinine could not. Likewise, significantly higher NGAL levels were
found in patients immediately after kidney transplantation that developed acute rejection
[11].
Recent studies could more or less confirm these results by analysing NGAL after kidney
transplantation from expanded criteria donors [12, 13]. Cantaluppi et al. even showed tacroli-
mus-induced increase of serum NGAL suggesting a role as marker of drug toxicity [13].
The aim of our study was to examine serial serum and urinary NGAL expression in the
early postoperative phase after kidney transplantation and to verify the significance of NGAL
in predicting DGF and acute allograft rejection.
Material and methods
Patient selection
170 consecutive patients with end-stage renal disease undergoing kidney transplantation from
October 2010 to December 2012 were prospectively enrolled after signed informed consent at
our institution. Exclusion criteria were age less than 18 years, retransplantation and combined
transplantation with another organ. None of the transplant donors were from a vulnerable
population and all donors or next of kin provided written informed consent that was freely
given. The study was approved by the Institutional Review Board (UN3710; Ethics Committee,
Innsbruck Medical University).
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Sample collection and measurement of laboratory parameters
Serum and urine samples of 170 patients undergoing primary kidney transplantation were col-
lected preoperatively and postoperatively from day one to 7 or discharge from hospital respec-
tively. Preoperative samples were taken prior to surgery. Postoperative samples were taken
during routinely performed blood collection in the morning. This was also the case with sam-
ples on postoperative day 1, these samples were not taken immediately after surgery. In six
patients it was not possible to obtain urine samples on postoperative day 1 and in two patients
on postoperative day 2 because of anuria. Urine collection was done via urinary catheter and
morning urine after catheter removal, respectively. Serum and urinary NGAL levels were mea-
sured by ELISA (Quantikine, R&D Systems, MN, USA). Serum creatinine was measured by
Jaffe method (Roche Diagnostics). Graft ultrasound was performed routinely and biopsies of
the grafts were only performed on clinical assumption of graft rejection.
Statistics
Absolute and relative frequencies are presented for nominal variables. To evaluate prospective
diagnostic power receiver operating characteristic (ROC) curves including AUC data were
generated at 48 hours after kidney transplantation. We used the CHI2-Test to compare cate-
gorical variables. T-test were applied to test parametric variables between groups and Mann-
Whitney U tests in the non-parametric case, respectively. Multivariate analyses were per-
formed by using a logistic regression model and by establishing a Cox proportional hazards
model for time-to-event analyses. For all analyses, a p-value <0.05 was defined as statistically
significant. Confidence intervalls (CI) were calculated on a 95% level. Statistical analyses were
performed using the SPSS version 24.0 for Windows.
Results
Our study sample included 170 recipients. Sociodemographical data and baseline characteris-
tics are shown in Table 1. Fifty-two patients developed delayed graft function which was
defined by the need for dialysis within the first week after transplantation according to the
United Network for Organ Sharing [14]. In the DGF group, recipients and donors were older
and ischemia time was longer, these data were significantly different. Charlson comorbidity
index, duration and type of preoperative dialysis were comparable in both groups. In four
patients acute rejection episodes were biopsy-proven (Patient #2: acute humoral rejection
BANFF I focal low positive for C4d; Patient #32: cellular rejection BANFF IA focal low positive
for HLA DR and C4d negative; Patient #57: acute cellular rejection BANFF IIB c4d negative;
Patient #158: acute humoral rejection BANFF II c4d negative). None of the four patients devel-
oped donor specific antibodies. 165 patients received a calcineurininhibitor and mycopheno-
latmofetil-based immunosuppression therapy with or without induction therapy with
basiliximab. Because of reasons of medical history and AB0 incompatible living donation five
patients received immunosuppression as follows: Patient #33: Basiliximab, calcineurine inhibi-
tor (CNI), Azathioprine (AZA), Methylprednisolon (MP); Patient #52: Campath, CNI, Myco-
phenolatmofetil (MMF), MP; Patient #92: Basiliximab, MMF, MP; Patient #140: Rituximab,
immunoglobulin apheresis, CNI, MMF, MP; Patient #143: anti-thymoglobin, CNI, MMF,
MP). Twenty patients underwent living donor kidney transplantation.
Postoperative creatinine, urine output and serum and urinary NGAL levels
To demonstrate differences in the expression profiles of typical surrogate parameters of kidney
function and NGAL, serum and urinary NGAL levels, serum creatinine and urine output was
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measured from postoperative day 1 to 7. Recipients were divided into two groups (DGF versus
primary function). Table 2 shows median values of serum und urinary NGAL, serum creati-
nine and urine output levels from postoperative day 1 to 7 in both groups. To avoid bias, data
are also shown without living donation kidney transplantations as DGF occurs rarely in these
patients. Expectedly, all surrogate parameters were higher in the DGF group compared to
patients with primary function.
Prediction of DGF by serum and urinary NGAL
To assess the predictive value of serum and urinary NGAL to detect DGF receiver operating
characteristic (ROC) analyses was performed. Regarding the area under the ROC curve
(AUC), urinary and serum NGAL could predict DGF highly accurate at second postoperative
day compared to serum creatinine (Fig 1). The AUC was highest for urinary NGAL (0.872) fol-
lowed by serum NGAL (0.869). Higher AUC levels of urinary and serum NGAL on POD 2
compared to POD 1 demonstrate the prognostic value of prediction of DGF at this time point.
Predictable power of NGAL could be demonstrated for both urine and serum NGAL as early
as POD 1. Likewise, the AUC for urine output is highest on POD 2 with highly accurate
Table 1. Sociodemographical data of 170 kidney recipients and donors.
Overall Primary function DGF p
N = 170 N = 118 N = 52
Patient baseline/preoperative data
Recipient sex (N—female) 61 (36%) 44 (37%) 17 (33%) 0.6
Recipient age (Mean / SD) 55 (14) 54 (14) 59 (12) 0.02
Donor age (Mean / SD) 54 (16) 52 (15) 60 (15) <0.001
HLA missmatches (Mean / SD) 3 (1.5) 3 (1.6) 4 (1.3) 0.08
Ischemia time (minutes, Mean / SD) 763 (329) 716 (347) 867 (258) 0.002
Charlson Comorbidity Index (Mean / SD) 2.8 (1.2) 2.7 (1.1) 3.1 (1.5) 0.1
Type of Dialysis (N—HD) 113 (67%) 74 (74%) 39 (85%) 0.2
Duration of Dialysis (months, mean / SD) 45 (28) 42 (30) 51 (24) 0.09
Diuresis pretransplant (N—yes) 100 (59%) 71 (69%) 29 (62%) 0.4
Diuresis pretransplant (lt, median / IQR) 0.9 (1.5) 1.0 (1.7) 0.7 (1.2) 0.09
Living donation 20 (12%) 20 (17%) 0
Clinical outcome
Episode of acute rejection 4 (2%) 0 4 (8%)
Graft loss after 1 year 14 (8%) 6 (5%) 8 (15%)
Death after 1 year 9 (5%) 5 (4%) 4 (8%)
Graft loss after 2 years 19 (11%) 7 (6%) 12 (23%)
Death after 2 years 11 (7%) 5 (4%) 6 (12%)
Graft loss after 5 years 30 (18%) 14 (12%) 16 (31%)
Death after 5 years 15 (9%) 8 (7%) 7 (14%)
initial immonosuppression
CNI, MP, MMF 37 (22%) 31 (26%) 6 (12%)
Basiliximab, CNI, MP, MMF 128 (75%) 83 (70%) 45 (87%)
other 5 (3%) 4 (3%) 1 (2%)
DGF: delayed graft function; SD: standard deviation; CNI: calcineurine inhibitors; MP: Methylprednisolon; MMF: Mycophenolatmofetil; IQR: interquartile range; HD:
Haemodialysis
https://doi.org/10.1371/journal.pone.0189932.t001
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prediction of DGF (0.883). Interestingly, compared to creatinine, serum and urinary NGAL,
the AUC decreases on POD 7 (0.713) regarding urine output.
Association of NGAL and DGF, graft and patient survival
To test independent parameters for DGF with regard to NGAL expression, multivariate analy-
ses were performed. Multivariate analyses including clinically relevant factors (recipient and
donor age, cold ischemia time, HLA mismatch) revealed that serum and urinary NGAL were
independent predictors of DGF on POD 2 compared to serum creatinine at this time point
(Table 3). Furthermore, urine output at this time point remained independently associated
with DGF. Data are also shown without living donation kidney transplantation with similar
results. Cox regression model for graft loss and patient death (with or without functioning
graft) two years and five years after transplantation (Table 4) identified recipient age as the
only independent prognostic factor for patient loss. Two years after transplantation, recipient
age is also an independent prognostic factor for graft loss.
Table 2. Creatinine, urinary NGAL, serum NGAL and urinary output levels from postoperative days 1–7.
creatinine mg/dl (median/IQR) d1 d2 d3 d4 d5 d6 d7
overall 6,6 [4,9–8,8] 5,1 [3,7–6,6] 4,2 [3–5,9] 3,6 [2,2–5] 2,8 [1,7–4,6] 2,2 [1,5–4,3] 2 [1,4–3,5]
primary function overall 6,5 [4,7–8,8] 4,6 [3,5–6,4] 3,7 [2,8–4,9] 2,6 [1,8–3,9] 2,1 [1,5–3] 1,7 [1,3–2,3] 1,5 [1,2–2,1]
primary function without living
donation
6,5 [4,6–8,9] 4,6 [3,7–6,1] 3,7 [2,8–4,9] 2,7 [1,8–3,9] 2,1 [1,5–3] 1,7 [1,3–2,6] 1,6 [1,1–2,2]
DGF 6,8 [5,6–9,1] 5,6 [4,2–7,1] 5,8 [4,6–7,3] 5,4 [4,4–7,3] 5,4 [4,3–7,5] 5,3 [3,7–6,6] 4,5 [3,4–5,8]
serum NGAL ng/ml (median/
IQR)



























































urinary NGAL ng/ml (median/
IQR)





39 [19,5–128,5] 29 [15,7–99,5] 22 [12,6–57,9] 17,3 [9,6–45,8] 15,3 [8,7–49,2]
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urine output liter (median/IQR) d1 d2 d3 d4 d5 d6 d7
overall 2,23 [1,275–
3,48]




2,58 [1,8–3,255] 2,46 [1,88–3,22] 2,6 [2,06–3,205]
primary function 2,8 [1,97–3,9] 3,06 [2,58–4,15] 2,93 [2,35–3,85] 2,75 [2,15–3,62] 2,87 [2,3–3,53] 2,8 [2,23–3,34] 2,85 [2,2–3,4]
primary function without living
donation




















DGF: delayed graft function; IQR: interquartile range
https://doi.org/10.1371/journal.pone.0189932.t002
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Discussion
DGF after kidney transplantation is a persistent problem ranging from 25.5% of deceased-
donor [15] to 3–5% of living-donor recipients [16]. In our series, DGF occurred in 30.6%
Fig 1. Receiver-operating characteristic (ROC) curves for urine output, serum NGAL, urinary NGAL and serum creatinine at posttransplant day 1, 2 and 7 (POD
1,2,7) for predicting delayed graft function.
https://doi.org/10.1371/journal.pone.0189932.g001
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Table 3. Univariate and multivariate analyses to identify predictors of DGF.




OR (95% CI) P HR (95% CI) P OR (95% CI) P HR (95% CI) P
Sex f>m 1.2 [0.6–2.4] 0.6 1.3 [0.6–2.6] 0.5
recipient age (per 10 years) 1.4 [1.0–1.8] 0.02 0.9 [0.5–1.6] 0.6 1.2 [0.9–1.6] 0.1 0.8 [0.3–2.0] 0.6
donor age (per 10 years) 1.5 [1.2–2] 0.002 1.7 [0.9–3.1] 0.1 1.5 [1.1–1.9] 0.005 1.7 [0.7–3.9] 0.3
HLA Missmatches 1.2 [0.97–1.5] 0.08 1.0 [0.7–1.6] 0.8 1.3 [1.0–1.6] 0.04 0.7 [0.4–1.1] 0.2
cold ischemia time (per 5hrs) 1.6 [1.1–2.2] 0.007 0.9 [0.5–1.8] 0.8 1.2 [0.8–1.7] 0.4 0.8 [0.3–2.0] 0.7
creatinine POD1 (per 1 unit) 1.05 [0.9–1.2] 0.4 1.1 [0.9–1.2] 0.4
creatinine POD2 (per 1 unit) 1.2 [1.0–1.4] 0.03 0.9 [0.7–1.3] 0.6 1.2 [1.0–1.4] 0.02 0.9 [0.7–1.2] 0.6
creatinine POD7 (per 1 unit) 7.8 [4.1–15.0] < 0.001 7.1 [3.7–13.4] < 0.001
serum NGAL POD1 (per 50 units) 2.2 [1.5–3.2] < 0.001 2.0 [1.4–2.9] < 0.001
serum NGAL POD2 (per 50 units) 4.4 [2.8–6.8] < 0.001 2.6 [1.4–4.9] 0.003 4.0 [2.6–6.2] < 0.001 2.6 [1.4–4.8] 0.003
serum NGAL POD7 (per 50 units) 6.6 [3.6–12.0] < 0.001 6.0 [3.3–10.8] < 0.001
urinary NGAL POD1 (per 50 units) 1.6 [1.3–1.9] < 0.001 1.6 [1.3–1.9] < 0.001
urinary NGAL POD2 (per 50 units) 2.4 [1.8–3.2] < 0.001 1.7 [1.2–2.5] 0.003 2.3 [1.8–3.1] < 0.001 1.7 [1.2–2.5] 0.003
urinary NGAL POD7 (per 50 units) 7.5 [3.8–14.8] < 0.001 6.7 [3.5–13.1] < 0.001
urinary output POD1 (per 100ml) 0.87 [0.8–0.9] < 0.001 0.9 [0.83–0.92] < 0.001
urinary output POD2 (per 100ml) 0.88 [0.8–0.9] < 0.001 0.9 [0.9–1.0] 0.001 0.9 [0.84–0.92] < 0.001 0.94 [0.9–1.0] 0.001
urinary output POD7 (per 100ml) 0.91 [0.87–0.96] < 0.001 0.9 [0.87–0.95] < 0.001
OR: odds ratio; HR: hazard ratio; CI: confidence interval; POD: postoperative day; DGF: delayed graft function
https://doi.org/10.1371/journal.pone.0189932.t003
Table 4. COX regression model to identify predictors for graft loss and death 2 and 5 yrs after KTx.
Variable multivariate analysis 2 yrs after transplantation
graft loss death of patient
HR (95% CI) P HR (95% CI) P
Sex f>m 0.5 (0.1–1.6) 0.2 0.4 (0.1–1.8) 0.2
recipient age (per 10 years) 5.2 (2.0–13.7) 0.001 5.3 (1.6–17.8) 0.007
donor age (per 10 years) 0.9 (0.6–1.3) 0.6 0.9 (0.6–1.4) 0.6
HLA Missmatches 0.9 (0.6–1.2) 0.4 1.1 (0.7–1.7) 0.7
cold ischemia time (per 5hrs) 1.2 (0.6–2.2) 0.6 1.5 (0.7–3.4) 0.3
creatinine POD2 (per 1 unit) 1.0 (0.7–1.3) 0.8 1.1 (0.7–1.5) 0.8
serum NGAL POD2 (per 50 units) 1.7 (1.0–2.8) 0.056 1.3 (0.7–2.285) 0.5
urinary NGAL POD2 (per 50 units) 1.0 (0.8–1.4) 0.8 1.2 (0.9–1.7) 0.3
Variable multivariate analysis 5 yrs after transplantation
graft loss death of patient
HR (95% CI) P HR (95% CI) P
Sex f>m 0.6 [0.2–1.3] 0.19 0.6 [0.2–2.1] 0.38
recipient age (per 10 years) 1.5 [0.9–2.4] 0.1 3.7 [1.4–9.6] 0.01
donor age (per 10 years) 1.1 [0.8–1.5] 0.53 1.0 [0.6–1.6] 0.91
HLA Missmatches 1.0 [0.7–1.3] 0.8 1.1 [0.8–1.7] 0.51
cold ischemia time (per 5hrs) 1.0 [1.0–1.0] 0.59 1.0 [1.0–1.0] 0.61
creatinine POD2 (per 1 unit) 0.9 [0.7–1.1] 0.34 0.9 [0.6–1.2] 0.41
serum NGAL POD2 (per 50 units) 1.2 [0.8–1.8] 0.28 1.2 [0.7–1.9] 0.56
urinary NGAL POD2 (per 50 units) 1.2 [1.0–1.5] 0.06 1.2 [0.9–1.6] 0.2
HR: hazard ratio; CI: confidence interval; POD: postoperatve day; KTx: kidney transplantation
https://doi.org/10.1371/journal.pone.0189932.t004
Prediction of DGF by serum and urinary neutrophil gelatinase-associated lipocalin after kidney transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0189932 January 5, 2018 7 / 11
when defining DGF as the need for dialysis in the first week post-transplant [17]. There are
various definitions of DGF in literature. Hollmen et al [12] compared the conventional DGF
definition with the DGF criteria defined by Halloran [18] with no significant differences in uri-
nary NGAL expression in their patient population. Recently, Moore at al defined DGF as fail
of decrease of serum creatinine by 10% on three consecutive days during the first week after
transplantation. Median creatinine values in Table 2 also meet these criteria.
Currently, serum creatinine is the most frequently used clinical parameter of post-trans-
plant kidney function although inaccuracy is given due to the impact of age, sex and muscle
mass on creatinine generation [19]. Furthermore, the ability of creatinine to detect functional
impairment is less than 50% [12]. Therefore, an intense research is ongoing to identify various
possible biomarkers in the early postoperative phase that help predicting DGF. Some publica-
tions recently revealed NGAL to predict DGF with more or less high accuracy in urine and
serum samples post-transplant [12–13, 20–22]. Weakness of most of these studies is low
patient number except the work done by Hollmen et al. [12] with a comparable number to the
study presented here. We found that urinary and serum NGAL could predict DGF most highly
accurate at second postoperative day. These results are similar to studies by Fonseca and Ros-
tami [22–23]. The study by Hollmen [12] and other works on NGAL after kidney transplanta-
tion showed that the earliest samples have best prediction power, but not showing NGAL on
postoperative day 2. Our data confirm these results with regard to sensitivity analyses in previ-
ous studies.
Diuresis, serum creatinine and the need for dialysis are clinical parameters that help to
define DGF. Diagnosis might be delayed especially in the early phase after transplantation
due to heterogeneous impact factors such as IRI and higher immunosuppressant levels. To
improve patient management it is important to individualize patient care as early as possible.
To our knowledge, there is no established treatment for DGF. But graft function can be
improved by avoiding overdialysis and nephrotoxic agents, for example adjusting the dose and
initiation of calcineurin inhibitors [24]. This immunosuppressant monitoring especially dur-
ing the early posttransplant phase might be a useful tool for improved future graft function.
We tried to correlate NGAL with CNI-levels as possible novel tool for immunomonitoring,
however not significantly predictive. A CNI-induced increase in NGAL levels could not be
observed in our patients in contrast to the description by Cantaluppi et al. [13].
NGAL is expressed in different cells and tissues and plays an important role during IRI
[25]. NGAL is produced in the distal nephron [26]. In previous studies, our group demon-
strated, that recombinant NGAL, which is administered to NGAL-knockout mice, was upta-
ken by the proximal tubular cells and can be detected in the urine as proof of filtration from
the blood [2]. These findings let us speculate that NGAL is not only a marker of tubular dam-
age but also a filtration marker, but this requires further investigation. NGAL was tracked in
both serum and urine compared to several other studies describing only urinary NGAL
expression [12, 23, 27–29]. In multivariate analyses we could show, that urinary NGAL as well
as serum NGAL can significantly predict DGF on the second postoperative day but not creati-
nine. These findings are in contrast to a study by Buemi et al [30] that proved only serum
NGAL to be a reliable predictor of DGF occurrence but not urinary NGAL. In contrast to Bue-
mi’s study our study population comprised a much higher number of patients (n = 170).
In univariate analyses cold ischemia time was significantly shorter in the non-DGF group.
Reduction of ischemia time but also other factors like the use of machine perfusion have been
demonstrated beneficial to decrease the rate of DGF [31]. The expression of NGAL in the latter
setting could be interesting for future studies of monitoring graft function with sustained per-
fusion during cold ischemia time.
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Using a Cox regression model for graft loss and patient death two and five years after trans-
plantation we identified only recipient age as an independent risk factor. Therefore, strategies
to spread the indication of donor organs is strikingly demanded to face the organ shortage and
shorten waiting lists like raising the amount of grafts from expanded criteria donors [32]. As
described before, NGAL detection is proposed a useful monitoring tool for those settings [12].
Strengths of the study presented here are the appreciable sample size and a long-term follow
up of five years. We present a consistently evaluation of urinary NGAL, serum NGAL and
urine output from postoperative day 1 to 7 after kidney transplantation as sort of monitoring
tool. These clinical data confirm our previous findings of increase in NGAL/Lipocalin-2 levels
in terms of acute graft rejection [33]. Major drawback of this study is the heterogeneous
patient cohort of unselected donors and recipients.
Conclusion
DGF remains a problem with high incidence that affects nearly every third patient in our pop-
ulation. As we cannot change patient and recipient age we have to minimize risk factors for
developing DGF that can be influenced, e.g. cold ischemia time. Determination of serum and
urinary NGAL can help predicting DGF early after kidney transplantation and may improve
graft function by close monitoring, fluid management and adaption of immunosuppression in
the longrun.
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